Trial Profile
A Multi-Center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Amifostine
- Indications Multiple myeloma; Various toxicities
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2015 Results published in the Bone Marrow Transplantation.
- 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Dec 2012 Primary endpoint `Major clinical response rate (near complete response and better)' has been met, according to the abstract presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.